Comparing the current results to its competitors, Glucotrack Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.76 %, recorded in the same quarter.
Glucotrack Inc 's Comment on Competition and Industry Peers
The continuous glucose monitoring (CGM) device market is highly competitive and rapidly evolving, with Abbott Laboratories, DexCom, and Medtronic accounting for the majority of worldwide CGM system sales. These companies offer transcutaneous systems featuring sensor lifespans of 7 to 15 days, typically worn on the back of the upper arm or abdomen. All four competitors, including the reporting company, are publicly traded or part of publicly traded entities. They possess competitive advantages such as established brand recognition, relationships with healthcare professionals, customers, and third-party payors, established distribution networks, additional product lines, and the capacity to offer rebates or bundled products. They also have extensive experience in research and development, manufacturing, clinical trials, regulatory approvals, marketing, and greater financial and human resources for product development, sales, marketing, and patent litigation.
DarioHealth Corp's business model revolves around providing digital health solutions to individuals with chronic diseases. Through their mobile health platform, they offer personalized tools and remote monitoring capabilities that empower patients to proactively manage their conditions. By combining software, data analytics, and medical devices, DarioHealth aims to enhance patient engagement, improve health outcomes, and reduce healthcare costs.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Dexcom Incs business model focuses on developing and selling continuous glucose monitoring systems for diabetes management. Their products provide real-time glucose level tracking, enabling users to better manage their condition through data-driven insights.
Sources:
Glucotrack Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Glucotrack Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
